Search
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexCannabidivarin
go.drugbank.com/drugs/DB14050Investigationaltheir physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors, the investigational cannabinoids with anticonvulsant action mostly use mechanisms that do … Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within [DB14009].
Reproxalap
go.drugbank.com/drugs/DB16688Investigational[L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis
Benzonatate
go.drugbank.com/drugs/DB00868Approved[A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug. … Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age.
Products: D-TATOAldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. … Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2.
Products: PROLEUKIN 18X106 IU/ML STERİL IV LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADETMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalbeginning of a new wave of treatment options for patients suffering from insomnia. … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Asparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.
Ibopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Dopamine D1 Receptor Agonists, Compounds used in a research, industrial, or household setting